Childrens Coltalin Tablet, Chewable
NDC Package 51467-006-01
Package Information
Childrens Coltalin (acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride) tablets is classified as a
administered via oral route. This formulation utilizes a tablet, chewable delivery system. Marketed by Fortune Pharmacal Company Limited, this product is identified by NDC 51467-006 and is authorized under FDA application M012.Identification & Billing
- RxCUI: 1540507 - acetaminophen 80 MG / chlorpheniramine maleate 0.5 MG / phenylephrine HCl 1.25 MG Chewable Tablet
- RxCUI: 1540507 - acetaminophen 80 MG / chlorpheniramine maleate 0.5 MG / phenylephrine hydrochloride 1.25 MG Chewable Tablet
- RxCUI: 1540507 - APAP 80 MG / Chlorpheniramine Maleate 0.5 MG / Phenylephrine Hydrochloride 1.25 MG Chewable Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 51467 - Fortune Pharmacal Company Limited
- 51467-006 - Childrens Coltalin
- 51467-006-01 - 24 TABLET, CHEWABLE in 1 CARTON
- 51467-006 - Childrens Coltalin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51467-006-01 identifies a specific commercial package of 24 tablet, chewable in 1 carton of Childrens Coltalin, a human over the counter drug labeled by Fortune Pharmacal Company Limited. This tablet, chewable is formulated for oral use and contains acetaminophen; chlorpheniramine maleate; phenylephrine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Fortune Pharmacal Company Limited on March 01, 2004. The current certification is valid through December 31, 2026.
How is this Fortune Pharmacal Company Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51467000601. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.